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Abstract
Aim—Conduct a systematic review with meta-analysis to determine the association between 
incident chemotherapy-induced neutropenia (CIN) and either diabetes mellitus (DM) or 
hyperglycemia in patients with cancer.
Methods—Observational studies in cancer patients of any age receiving chemotherapy and 
having diabetes or hyperglycemia either during or before chemotherapy induction were included. 
Studies were retrieved by searching four databases (PubMed, EBSCO, ProQuest, and Cochrane) 
and cross-referencing. The metric for combining studies was the odds ratio (OR). Results were 
pooled using a random-effects model, while heterogeneity and inconsistency were assessed using 
the Q and I2 statistic, respectively. Potential small-study effects were assessed using the funnel 
plot.
Results—Ten studies met the criteria for inclusion. Overall, the odds of having CIN were 32% 
higher among cancer patients with either DM or hyperglycemia compared with those without DM 
or hyperglycemia (OR = 1.32, 95% CI, 1.06–1.64). Statistically significant heterogeneity and 
inconsistency were found (Q = 33.15, p < 0.05, I2 = 72.9%). Funnel plot asymmetry reflecting 
potential small-study effects was observed.
Conclusions—Diabetes mellitus and hyperglycemia may be associated with an increased risk 
for CIN among cancer patients. However, additional well-designed studies are needed before any 
final and definitive recommendations can be made.
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Chemotherapy-induced neutropenia (CIN) is a hematologic toxicity caused by the cytotoxic 
effects of chemotherapy and which could lead to suppressing the production of neutrophils 
(Crawford, Dale, & Lyman, 2004). These cells are mature white blood cells made in the 
bone marrow and then released to the circulating blood as the first line of the body's defense 
against any infection (Crawford et al., 2004; “Neutropenia,” 2012). The threshold of 
absolute neutrophil count (ANC) in blood is approximately 2000 cells/mm3 (Lyman, Lyman, 
& Agboola, 2005). Consequently, the reduction in neutrophil counts below this threshold 
could weaken the body's immunity and increase its susceptibility to infection, especially in 
cancer patients.
Among cancer patients, CIN is a major cause of morbidity, hospitalization, mortality, and 
costs after chemotherapy induction (Lyman & Kuderer, 2003; Pettengell et al., 2012). A 
study conducted in the United Kingdom (UK) showed that the incidence of CIN was 27% in 
breast cancer patients, 16% in lung cancer patients, and 13% in ovarian cancer patients, with 
an average length of stay in hospitals of 9.2 days and an average cost of £2353 per patient 
(Schelenz, Giles, & Abdallah, 2012). The substantial incidence of CIN during therapy could 
lead to an undesired delay in treatment or reduction in the chemotherapy dose, thus, 
compromising the potential benefits of cancer treatment (Chen, Chan, & Yap, 2013; Heuser 
& Ganser, 2005; Lyman, Dale, Friedberg, Crawford, & Fisher, 2004).
Despite the high prevalence of CIN among cancer patients and its negative consequences on 
cancer outcomes, the possible risk factors associated with CIN have not been studied closely. 
In addition to common risk factors for the development of CIN such as age and the type of 
cancer, hyperglycemia and diabetes comorbidities could be associated with an increased risk 
in the incidence of CIN. Previous experimental studies have investigated that diabetes 
impairs neutrophil function by causing defects in chemotaxis and microbicidal activities 
(Alba-Loureiro et al., 2006; Bagdade, Nielson, & Bulger, 1972; Pereira, Sannomiya, & 
Leme, 1987). The metabolic disorders and changes in the processes of producing energy 
result in a reduction of neutrophil count since the generation of neutrophil cells requires 
energy (Alba-Loureiro et al., 2007). Therefore, it is plausible that diabetes and 
hyperglycemia may increase the risk of CIN among cancer patients as well. Hyperglycemia 
and diabetes mellitus (DM) could have a synergetic effect with chemotherapy on increasing 
the risk of CIN. However, since hyperglycemia and DM are previously unrecognized as risk 
factors for CIN, the collective evidence of their impact on developing CIN during 
chemotherapy among cancer patients is still lacking (Sonabend et al., 2008; Soysal et al., 
2012).
To the best of the authors' knowledge, no previous systematic review with meta-analysis has 
examined the association between DM or hyperglycemia and the risk of developing CIN 
after chemotherapy induction in cancer patients. This is important in determining the overall 
magnitude of association, if any, between DM or hyperglycemia and the risk of developing 
CIN after chemotherapy induction in cancer patients. Thus, the purpose of this study was to 
conduct a systematic review with meta-analysis to determine the association between DM or 
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hyperglycemia and the risk of developing CIN after chemotherapy induction in cancer 
patients.
2. Methods
2.1. Study eligibility criteria
The a priori inclusion criteria for this meta-analysis were as follows: (1) observational 
studies in cancer patients of any age receiving chemotherapy, (2) cases defined as those who 
developed CIN after chemotherapy induction, (3) comparison group, defined as patients who 
did not develop CIN during or after chemotherapy induction, (4) having either DM or 
hyperglycemia during or before chemotherapy induction, (5) studies reported in any 
language, (6) data reported for chemotherapy-induced neutropenia (CIN), defined as a 
dichotomous variable (no or yes) for analysis. Although DM and hyperglycemia are 
clinically heterogeneous entities, both were included because they have similar 
pathophysiological features during chemotherapy that influence the development of CIN 
incidence (Dungan, Braithwaite, & Preiser, 2009). Eligible studies included articles 
published in peer-reviewed journals as well as unpublished work in the form of theses and 
dissertations. Because of the potential for publication bias, i.e., tendency for authors to 
submit, and editors to publish, studies that yield statistically significant results, unpublished 
work in the form of theses and dissertations were also considered eligible. This eligibility 
criterion may be especially relevant given the potential lack of eligible studies addressing the 
impact of DM and/or hyperglycemia on the risk of CIN. This meta-analysis was not 
registered in any trial registry.
2.2. Data sources
Studies were retrieved using the following 4 electronic databases: (1) PubMed, (2) EBSCO, 
(3) ProQuest Dissertation and Theses, and (4) Cochrane Library. The search strategy focused 
on hyperglycemia or diabetes before or during chemotherapy and the incidence of CIN. No 
date or language filters were applied. All databases were searched from their inception up to 
April 26th, 2016. The starting search dates for each database, based on their inception dates, 
were as follows: (1) PubMed (1966), (2) EBSCO (1984), (3) ProQuest Dissertation and 
Theses (1861), and (4) Cochrane Library (1992).When necessary, the full text was obtained 
for all potentially eligible articles. Although the search strategies used varied according to 
the requirements of the different databases searched, keywords centered on the terms 
‘neutropenia’, ‘chemotherapy’ and ‘diabetes’ or ‘hyperglycemia’. An example of the search 
strategy for one database (PubMed) is as follows: “neutropenia AND (diabetes OR DM OR 
hyperglycemia) AND chemotherapy” Thereafter, a more general search was applied by 
focusing on the following since most cancer studies reported neutropenia cases under 
chemotherapy toxicity:
“(diabetes OR DM OR hyperglycemia) AND chemotherapy AND toxicity”
All database searches are shown in Supplementary file 1. In addition to electronic database 
searches, cross-referencing for potentially eligible studies and retrieved reviews was also 
conducted. All studies were stored in EndNote™ basic (“EndNote,” 2016). All searches 
were conducted by the first author with guidance from the second author.
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2.3. Study selection and data abstraction
The list of the both included and excluded studies as well as reasons for exclusion was 
stored by the first author in Microsoft Excel 2013. A codebook was created by the first 
author, with multiple items per each included study using Microsoft Excel 2013. The main 
variables that were coded included: (1) first author of study, (2) year when the studies' data 
was reported, (3) study design, (4) publication status, (5) country where the study was 
conducted, (6) funding, (7) age group (adults, elderly, or children), (8) definition of 
hyperglycemia or DM, (9) cutoff for having neutropenia based on ANC, (10) cancer type, 
and (11) number of patients included in each study. The primary outcome for this study was 
established a priori and defined as CIN incidence following chemotherapy for cancer 
patients. The main risk factor of interest was having either DM or hyperglycemia. Study 
selection and data abstraction were conducted by the first author with oversight from the 
second author.
2.4. Risk of bias
Risk of bias was assessed using the Strengthening the Reporting of Observational Studies in 
Epidemiology (STROBE) checklist (STROBE, EQUATOR Network, 2016). The STROBE 
instrument is a checklist of 22 items that assesses cohort, case-control, and cross sectional 
studies (Elm et al., 2007). Items are related to components that include the title, abstract, 
introduction, methods, results, and discussion sections. Some items include multiple 
components where studies had to meet all criteria in order to receive a positive evaluation for 
the item (Elm et al., 2007). Risk of bias was assessed by the first author with oversight from 
the second author.
2.5. Statistical analysis
Odds ratios (ORs) with 95% confidence intervals were calculated from included studies and 
pooled using a random-effects model that incorporates between-study variance into the 
estimate (DerSimonian & Laird, 1986). Data were analyzed using the log odds ratio and 
then converted back to the odds ratio for ease of interpretation. Ninety-five percent 
confidence intervals that did not include 1 were considered statistically significant. 
Heterogeneity and inconsistency were assessed using Cochran's Q test and the I2 statistic, 
respectively. An alpha value ≤0.10 on the Q test was considered to be representative of 
statistically significant heterogeneity, while an I2 statistic greater than 50% was considered 
to be indicative of substantial inconsistency (Kim, Lee, Choi, Huh, & Park, 2015). Funnel 
plots were used to visually examine for potential small-study effects (publication bias, etc.). 
In addition, influence analysis with each result deleted from the model once, as well as 
cumulative meta-analysis, ranked by year, was conducted. Furthermore, stratified analyses 
were performed according to (1) country the study was conducted in (USA versus other), (2) 
risk factor (DM versus hyperglycemia) and (3) adjustment for potential confounders (yes 
versus no). All analyses were conducted using MetaXL, version 5.0, (Barendregt, 2016) 
within Microsoft Excel 2013.
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Of the 157 articles screened, 10 peer-reviewed articles involving 8688 cases of CIN met all 
eligibility criteria (Fig. 1). A list of the 12 studies that were excluded after reviewing the full 
text is shown in Supplementary file 2. Nine studies assessed the risk of neutropenia 
incidence as one of the primary outcomes of interest after chemotherapy induction (Abou-
Saleh et al., 2013; Carmona-Bayonas et al., 2011; Chao et al., 2014; Chen et al., 2013; 
Crawford et al., 2008; Lyman et al., 2010; Sonabend et al., 2008; Soysal et al., 2012; 
Srokowski, Fang, Hortobagyi, & Giordano, 2009; Takenaka et al., 2013). One study used 
neutropenia as an exposure of interest to explore its impact on the overall mortality after 
chemotherapy reception (Lyman et al., 2010). Six studies reported DM as an exposure of 
interest or as one of the primary risk factors (Abou-Saleh et al., 2013; Carmona-Bayonas et 
al., 2011; Chao et al., 2014; Chen et al., 2013; Srokowski et al., 2009; Takenaka et al., 
2013), while two studies used DM as just a patient characteristic included in the study 
(Crawford et al., 2008; Lyman et al., 2010). Only two studies assessed hyperglycemia as an 
exposure of interest (Sonabend et al., 2008; Soysal et al., 2012).
Only one study was a prospective cohort study (Crawford et al., 2008), while the remaining 
9 were retrospective cohort studies (Abou-Saleh et al., 2013; Carmona-Bayonas et al., 2011; 
Chao et al., 2014; Chen et al., 2013; Lyman et al., 2010; Sonabend et al., 2008; Soysal et al., 
2012; Srokowski et al., 2009; Takenaka et al., 2013). Two of ten studies adjusted for 
potential confounding factors such as sex, demographics, cancer characteristics, year of 
diagnosis, comorbidities, and type of chemotherapy (Chao et al., 2014; Srokowski et al., 
2009), whereas the remaining studies reported crude OR or only frequencies of events 
(Abou-Saleh et al., 2013; Carmona-Bayonas et al., 2011; Chen et al., 2013; Crawford et al., 
2008; Lyman et al., 2010; Sonabend et al., 2008; Soysal et al., 2012; Takenaka et al., 2013).
A summary of results using the STROBE instrument can be found in Supplementary file 3, 
while detailed study and item-level findings are shown in Supplementary file 4. Overall, all 
the included studies provided a background and rationale for their research, reported the 
results of their outcomes, and summarized the key results with reference to study objectives 
in the discussion. The majority of studies indicated the study design clearly (n = 7), provided 
a summary in the abstract (n = 7), stated their objectives (n = 9), and described the study 
setting (n = 9). However, few studies identified potential sources of bias (n = 2), provided 
the source of funding (n = 2), clearly defined the variable considered during the studies 
(outcomes, predictors, and covariates) (n = 4), and described the source of data used for each 
variable (n = 4).
Variation across included studies was observed for setting, populations studied (age and 
cancer type), definition of the risk factor (DM or hyperglycemia), and definition of CIN 
(Table 1). Cancer types in each study included acute leukemia (Sonabend et al., 2008), 
multiple types of cancer (Abou-Saleh et al., 2013; Carmona-Bayonas et al., 2011; Chao et 
al., 2014; Crawford et al., 2008; Lyman et al., 2010; Soysal et al., 2012), neck and head 
cancer (Takenaka et al., 2013), breast cancer (Chen et al., 2013; Srokowski et al., 2009), and 
lymphomas (Chen et al., 2013). Two of the 10 studies examined hyperglycemia as a primary 
risk factor of interest (Sonabend et al., 2008; Soysal et al., 2012), one examined DM as a 
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primary risk factor (Srokowski et al., 2009), whereas the remaining seven considered DM as 
a potential confounder based on another association of interest (Abou-Saleh et al., 2013; 
Carmona-Bayonas et al., 2011; Chao et al., 2014; Chen et al., 2013; Crawford et al., 2008; 
Lyman et al., 2010; Takenaka et al., 2013). One study considered only children (Sonabend et 
al., 2008), another study considered only elderly (Crawford et al., 2008), whereas other 
studies considered adults (Abou-Saleh et al., 2013; Carmona-Bayonas et al., 2011; Chao et 
al., 2014; Chen et al., 2013; Lyman et al., 2010; Soysal et al., 2012; Srokowski et al., 2009; 
Takenaka et al., 2013). Five studies were conducted in the US (Chao et al., 2014; Crawford 
et al., 2008; Lyman et al., 2010; Sonabend et al., 2008; Srokowski et al., 2009), while others 
were conducted in Spain (Carmona-Bayonas et al., 2011), Finland (Soysal et al., 2012), 
Singapore (Chen et al., 2013), Oman (Abou-Saleh et al., 2013), and Japan (Takenaka et al., 
2013). For the definition of CIN, studies had different cut-off points for ANC and used 
different metrics. To facilitate the comparison between studies, all neutropenia metrics were 
converted into cells/mm3 since the majority used this metric. However, a study conducted by 
Srokowski et al. (2009) identified neutropenia cases by ICD-9 code of 288.0, and thus, no 
conversion was possible.
Across all designs and categories, the odds of having CIN was statistically significant, being 
32% higher among cancer patients when DM and hyperglycemia results were pooled 
together (Fig. 2). However, statistically significant heterogeneity and substantial 
inconsistency were observed. In addition, potential small-study effects were found (Fig. 3). 
With each study deleted from the model once, results remained statistically significant 
across all deletions (Supplementary file 5). Cumulative meta-analysis, ranked by year, 
revealed that results have remained statistically significant since only 2013 (Supplementary 
file 6).
Overall findings for stratified analyses are shown in Table 2, while study-level results are 
shown in Supplementary file 7. As can be seen, results were statistically significant and in 
the direction of an increased risk for CIN for other countries but not the United States. For 
risk factors, statistically significant odds ratios in the direction of increased risk were 
observed for hyperglycemia but not DM. In contrast, both crude and adjusted estimates were 
statistically significant and in the direction of an increased risk for CIN. No between-group 
differences, as judged by non-overlapping confidence intervals, were observed between any 
of the groups (Okera et al., 2011).
4. Discussion
4.1. Overall findings
This study set out to conduct a systematic review with meta-analysis to determine whether 
hyperglycemia and DM are associated with an increased risk for CIN among cancer patients. 
Overall, the results of this systematic review with meta-analysis of 10 observational studies 
suggest that DM and hyperglycemia may be associated with an increased risk for CIN 
among cancer patients after chemotherapy induction. These findings persisted when each 
study was deleted from the model once and have been statistically significant since 2013. 
Importantly, the use of a random-effects model incorporated between-study variance into the 
model, thus, resulting in more conservative findings when compared to a fixed-effect model.
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4.2. Implications for research
The results of this study provide at least two implications for research. First, a statistically 
significant and substantial amount of unexplained heterogeneity and inconsistency was 
observed. Thus, while a random-effects model incorporates between-study heterogeneity 
into the model, it does not explain the source(s) from which such heterogeneity and 
inconsistency are derived. Along those lines, our stratified analyses suggested a continued 
association for CIN when (1) studies were conducted in countries other than the United 
States, (2) hyperglycemia but not DM was the risk factor examined, and (3) either crude or 
adjusted estimates were used. While these findings are interesting and may be worthy of 
further study, they are based on small samples and were examined separately versus being 
included in a larger multiple meta-regression model. However, as is the case with many 
meta-analyses, multiple meta-regression is often not possible due to the small number of 
studies included in a meta-analysis as well as missing data for different variables from 
different studies.
Second, the quality of reporting and/or conduct of studies on this topic could be improved. 
For example, based on the STROBE checklist, only five studies score at 75% or higher. 
More specifically, 40% or less of the included studies reported adequate information with 
respect to funding sources as well as methodological issues such as bias, data sources and 
variables. Given the former, it is suggested that future studies address these issues. More 
specifically, since only two of ten included studies adjusted for potential confounders (Chao 
et al., 2014; Srokowski et al., 2009), it is suggested that future studies on this topic include 
both crude and adjusted estimates.
4.3. Implications for practice
This finding supports a previous recommendation regarding pretreatment assessment of CIN 
risk factors such as hyperglycemia to avoid hospitalization and mortality associated with 
CIN incidence after chemotherapy induction (Crawford et al., 2008). Unfortunately, 
Sonabend et al. reported that although hyperglycemia was common among cancer patients 
who received chemotherapy induction, only a few were treated with insulin (Sonabend et al., 
2008).
4.4. Strengths and limitations
From our perspective, the major strength of this study is the fact that to the best of our 
knowledge, this is the first systematic review with meta-analysis to examine the association 
between hyperglycemia and DM and the risk of CIN among cancer patients. Thus, this study 
provides important information for clinical consideration when prescribing chemotherapy as 
well as future research, both original and meta-analytic. Alternatively, there are at least five 
potential limitations to this study. First, given that only 10 studies met our inclusion criteria, 
it appears that the number of studies that have addressed this issue is small. Given the 
potential importance, it is suggested that future observational studies on this topic are 
needed. Second, like any aggregate data (not an individual patient data) meta-analysis, this 
study is prone to ecological fallacy. This suggests that our pooled findings may not occur at 
the individual level. Third, the included studies were heterogeneous in terms of the reasons 
why the studies were conducted, as well as the patients included in each study. Thus, it could 
Alenzi and Kelley Page 7













be argued that combining one or more of these studies in the current meta-analysis may not 
have been appropriate. Fourth, the odds ratios for 8 of the 10 included studies were 
unadjusted, thus, presenting the possibility of residual confounding. Fifth, since dual-
selection, abstraction, and risk of bias assessment did not occur in the current meta-analysis, 
an increased risk of errors was possible.
5. Conclusions
The results of this systematic review with meta-analysis suggest that DM and hyperglycemia 
may be associated with an increased risk of CIN among cancer patients. However, given the 
substantial heterogeneity observed, additional well-designed studies are needed before any 
final and definitive recommendations can be made.
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Flow diagram that describes the search process.
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Forest plot of the association between DM/hyperglycemia and CIN in cancer patients. OR 
and 95% CI indicate odds ratio and 95% confidence interval.
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Funnel plot for small-study effects.
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